Clinical trials: Ejection Fraction
Heart Failure
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)
Objective of the study is to find the optimal dose of the once daily oral soluble guanylate cyclase stimulator (sGC) BAY1021189 for Phase III that can be given in addition to standard therapy for heart failure with reduced…
- Trial name
- NCT01951625
- Testing
- Vericiguat (BAY1021189) (1.25 mg), Vericiguat (BAY1021189) (5 mg)
- Where
- 157 sites in United States, Australia and 22 more
- Volunteers
- 456 people
- Sponsor
- Bayer
Heart Failure
Effect of Pre-Hospital ARNI Therapy on Short-Term Outcomes in HFrEF
This study looks at people with heart failure who are admitted to the hospital. The goal of the study is to understand whether taking a heart failure medicine called angiotensin receptor-neprilysin inhibitor (ARNI) before…
- Trial name
- NCT07347925
- Testing
- Prehospital ARNI use, No prehospital ARNI use
- Where
- Egypt
- Volunteers
- 140 people
- Sponsor
- Future University in Egypt
Heart Failure with Reduced Ejection Fraction
Left Bundle Branch Area Pacing Using Conventional Stylet-driven Pacemaker Leads for Cardiac Resynchronization Therapy
The aim of this study proposal is to compare the effectiveness of two distinct pacing modalities for cardiac resynchronization therapy.
- Trial name
- LeCaRT (NCT05365568)
- Testing
- Left Bundle Branch Area Pacing (LBBAP), Biventricular pacing (BiV)
- Where
- 11 sites in Belgium
- Volunteers
- 170 people
- Sponsor
- AZ Sint-Jan AV
Acute Coronary Syndrome
Class IV Laser Therapy on Ejection Fraction, Cardio Biomarkers and Functional Outcomes
A total of 60 Individuals with Acute coronary Syndrome who underwent angioplasty with or without stent will be recruited by purposive sampling method in a randomized double-blinded sham controlled trial.
- Trial name
- NCT05160519
- Testing
- Class IV Laser
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Asir John Samuel
Heart Failure With Reduced Ejection Fraction
Safety of HMA-CD20 in Patients With HFrEF
The study is a phase II single-centered, single group, prospective clinical trial to evaluate the safety of HMA-CD20 doses among stable patients with class III/IV according to the NYHA classification with HFrEF receiving standard…
- Trial name
- ICFEr-RITU2 (NCT03332888)
- Testing
- Rituximab
- Volunteers
- 10 people
- Sponsor
- Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud
Heart Failure With Preserved Ejection Fraction, Microvascular Coronary Artery Disease
Reversing Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction
This study will evaluate the impact of colchicine on the change in coronary flow reserve (CFR), a marker for coronary microvascular dysfunction (CMD), compared to placebo in patients with heart failure and ejection fraction above…
- Trial name
- COL-Micro-HF (NCT06217120)
- Testing
- Colchicine
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Montreal Heart Institute
Heart Failure, Heart Failure, Systolic
COmparing arNi and Ace For Improving Erectile Dysfunction in mEN With reduCed Ejection Fraction Heart Failure
The purpose of this study was to determine the effect of sacubitril/valsartan (LCZ696) vs. Enalapril on improvement in erectile function and ability in male patients with chronic heart failure with reduced ejection fraction and…
- Conditions
- Heart Failure, Heart Failure, Systolic, Erectile Dysfunction
- Trial name
- CONFIDENCE-HF (NCT03917459)
- Testing
- LCZ696, Enalapril
- Where
- 13 sites in Germany
- Volunteers
- 27 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Left Bundle-Branch Block
Mid-Q Response Study
The Mid-Q Response study is a prospective, multi-center, randomized controlled, interventional, single-blinded, post-market study.
- Conditions
- Heart Failure, Left Bundle-Branch Block, Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure NYHA Class II
- Trial name
- NCT04180696
- Testing
- aCRT ON, aCRT OFF
- Where
- 61 sites in Brunei, China and 8 more
- Volunteers
- 177 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure With Reduced Ejection Fraction
VAgal Nerve Stimulation: safeGUARDing Heart Failure Patients
The purpose of the VANGUARD study is to demonstrate the safety of Vagal Nerve Stimulation for the treatment of congestive heart failure with reduced ejection fraction, and to report secondary measures of efficacy.
- Trial name
- VANGUARD (NCT02113033)
- Testing
- Equilia® Vagal Nerve Stimulation
- Where
- 6 sites in Belgium, France and 2 more
- Volunteers
- 15 people
- Sponsor
- LivaNova
Myocardial Infarction
TREatment With Beta-blockers After myOcardial Infarction withOut Reduced Ejection fracTion"
REBOOT clinical trial will study whether long-term maintenance beta-blockers therapy results in a clinical benefit after heart attack without reduced left ventricular function.
- Trial name
- NCT03596385
- Testing
- Beta blocker
- Where
- 111 sites in Italy, Spain
- Volunteers
- 8,505 people
- Sponsor
- Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
Heart Failure
Improving Goal Directed Medical Therapy for Device Clinic Patients With Reduced EF at UOHI: a QI Initiative (VIGILANT)
This is a quality improvement initiative with the goal of optimizing heart failure (HF) patients seen through the outpatient cardiac implantable electronic device clinic at the University of Ottawa Heart Institute (UOHI).
- Trial name
- VIGILANT (NCT05085249)
- Where
- Canada
- Volunteers
- 2,479 people, healthy volunteers welcome
- Sponsor
- Ottawa Heart Institute Research Corporation
Chronic Heart Failure (CHF)
Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction
This study was a multi-center, randomized, double-blind, parallel group, active comparator trial designed to evaluate the overall effect of LCZ696 compared to valsartan on cognitive function as assessed by the CogState…
- Trial name
- PERSPECTIVE (NCT02884206)
- Testing
- LCZ696, Valsartan
- Where
- 135 sites in United States, Argentina and 18 more
- Volunteers
- 592 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure With Reduced Ejection Fraction, Atrial Fibrillation (AF)
Optimal PharmacoTherapy and Invasive Management of Atrial Fibrillation in Patients With Heart Failure
Atrial Fibrillation (AF) and Heart Failure (HF) are colliding global cardiovascular epidemics, individually impairing quality of life and cardiac performance, as well as increasing the risk of hospitalisation and mortality.
- Trial name
- OPTIMal AF-HF (NCT07238452)
- Testing
- Pulmonary Vein Isolation, Pharmacological Rate Control
- Volunteers
- 1,050 people
- Sponsor
- University of British Columbia
Diastolic Heart Failure NYHA Class III-IV, Diastolic Dysfunction Secondary to Aortic Stenosis
CORolla™ TAA for Heart Failure and Preserved Ejection Fraction and Diastolic Dysfunction
The study purpose is to evaluate the safety and feasibility of the CORolla™ TAA in two treatment groups, "CORolla™ Stand-alone group" and " AVR \& CORolla™ Add on group".
- Trial name
- NCT01956526
- Testing
- CORolla™ TAA device
- Where
- 2 sites in Italy
- Volunteers
- 12 people
- Sponsor
- CorAssist Cadiovascular Ltd.
Heart Failure With Reduced Ejection Fraction (HF-rEF)
The Effectiveness and Safety of Artificial Intelligence(AI)-Assisted Medical Treatment Decision Support System Compared to Conventional Care in HFrEF Patients
This clinical trial aims to find out if using an artificial intelligence (AI) decision support system can help doctors better manage medications for people with heart failure with reduced ejection fraction (HFrEF).
- Trial name
- NCT07380555
- Testing
- artificial intelligence (AI) decision support system
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Shanghai Zhongshan Hospital
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Validation of a Machine Learning Predictive Model to Distinguish Post-capillary Pulmonary Hypertension
In this study the diagnostic accuracy of a diagnostic tool for the diagnosis of post-capillary pulmonary hypertension will be investigated.
- Conditions
- Pulmonary Hypertension, Pulmonary Arterial Hypertension, HFpEF - Heart Failure With Preserved Ejection Fraction
- Trial name
- Optiek 2-0 (NCT06405126)
- Testing
- Optiek predictive model
- Where
- 4 sites in Belgium
- Volunteers
- 100 people
- Sponsor
- KU Leuven
Heart Failure With Reduced Ejection Fraction
Initiation of ARNi and SGLT2i in Patients With HFrEF
Heart failure (HF) is a condition in which the heart does not contract ("pump") or relax well, leading to insufficient perfusion of vital organs.
- Trial name
- INITIATE (NCT05989503)
- Testing
- Sacubitril-valsartan, SGLT2 inhibitor
- Where
- 5 sites in Portugal
- Volunteers
- 62 people
- Sponsor
- Universidade do Porto
Heart Failure and Reduced Ejection Fraction
Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction
To determine whether treatment with sacubitril/valsartan provides a superior effect on aortic characteristic impedance compared to enalapril in patients with heart failure and reduced ejection fraction (left ventricular ejection…
- Trial name
- EVALUATE-HF (NCT02874794)
- Testing
- LCZ696 (sacubitril/valsartan), Enalapril
- Where
- 81 sites in United States
- Volunteers
- 465 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
Change of NLRP3 Inflammasome Expression Level, Symptoms, and Functional Status in HFpEF Patients Treated With ARNI
Underlying inflammation has been increasingly recognized in heart failure with a preserved ejection fraction(HFpEF). But there is no study reported the relationship between NLRP3 inflammasome and HFpEF.
- Trial name
- NCT04269057
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Chongqing Medical University
Systolic Heart Failure
Repurposing Probenecid as a Positive Inotrope for the Treatment of Heart Failure
Probenecid is an FDA approved drug for the treatment gout and hyperuricemia. It has been used safely in humans for decades for this and other indications.
- Trial name
- ReProsperHF (NCT01814319)
- Testing
- Probenecid 1 gr oral twice daily
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Cincinnati
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.